Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma? / Mouhammad, Zaynab Ahmad; Vohra, Rupali; Horwitz, Anna; Thein, Anna Sophie; Rovelt, Jens; Cvenkel, Barbara; Williams, Pete A.; Azuara-Blanco, Augusto; Kolko, Miriam.
I: Frontiers in Neuroscience, Bind 16, 824054, 2022.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?
AU - Mouhammad, Zaynab Ahmad
AU - Vohra, Rupali
AU - Horwitz, Anna
AU - Thein, Anna Sophie
AU - Rovelt, Jens
AU - Cvenkel, Barbara
AU - Williams, Pete A.
AU - Azuara-Blanco, Augusto
AU - Kolko, Miriam
N1 - Funding Information: This work was supported by Mauritzen La Fontaine Familiefond, the BRIDGE ? Translational Excellence Programme funded by the Novo Nordisk Foundation (Grant agreement no. NNF18SA0034956). PW was supported by Karolinska Institutet in the form of a Board of Research Faculty Funded Career Position and by St. Erik Eye Hospital philanthropic donations, Vetenskapsr?det 2018-02124. Publisher Copyright: Copyright © 2022 Mouhammad, Vohra, Horwitz, Thein, Rovelt, Cvenkel, Williams, Azuara-Blanco and Kolko.
PY - 2022
Y1 - 2022
N2 - Glaucoma is a common ocular neurodegenerative disease characterized by the progressive loss of retinal ganglion cells and their axons. It is the most common cause of irreversible blindness. With an increasing number of glaucoma patients and disease progression despite treatment, it is paramount to develop new and effective therapeutics. Emerging new candidates are the receptor agonists of the incretin hormone glucagon-like-peptide-1 (GLP-1), originally used for the treatment of diabetes. GLP-1 receptor (GLP-1R) agonists have shown neuroprotective effects in preclinical and clinical studies on neurodegenerative diseases in both the brain (e.g., Alzheimer’s disease, Parkinson’s disease, stroke and diabetic neuropathy) and the eye (e.g., diabetic retinopathy and AMD). However, there are currently very few studies investigating the protective effects of GLP-1R agonists in the treatment of specifically glaucoma. Based on a literature search on PubMed, the Cochrane Library, and ClinicalTrials.gov, this review aims to summarize current clinical literature on GLP-1 receptor agonists in the treatment of neurodegenerative diseases to elucidate their potential in future anti-glaucomatous treatment strategies.
AB - Glaucoma is a common ocular neurodegenerative disease characterized by the progressive loss of retinal ganglion cells and their axons. It is the most common cause of irreversible blindness. With an increasing number of glaucoma patients and disease progression despite treatment, it is paramount to develop new and effective therapeutics. Emerging new candidates are the receptor agonists of the incretin hormone glucagon-like-peptide-1 (GLP-1), originally used for the treatment of diabetes. GLP-1 receptor (GLP-1R) agonists have shown neuroprotective effects in preclinical and clinical studies on neurodegenerative diseases in both the brain (e.g., Alzheimer’s disease, Parkinson’s disease, stroke and diabetic neuropathy) and the eye (e.g., diabetic retinopathy and AMD). However, there are currently very few studies investigating the protective effects of GLP-1R agonists in the treatment of specifically glaucoma. Based on a literature search on PubMed, the Cochrane Library, and ClinicalTrials.gov, this review aims to summarize current clinical literature on GLP-1 receptor agonists in the treatment of neurodegenerative diseases to elucidate their potential in future anti-glaucomatous treatment strategies.
KW - antidiabtics
KW - glaucoma
KW - GLP-1 receptor agonists
KW - neurodegenerative diseases
KW - neuroprotection
KW - ophthalmology
U2 - 10.3389/fnins.2022.824054
DO - 10.3389/fnins.2022.824054
M3 - Review
C2 - 35264926
AN - SCOPUS:85125848004
VL - 16
JO - Frontiers in Neuroscience
JF - Frontiers in Neuroscience
SN - 1662-4548
M1 - 824054
ER -
ID: 300333359